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Abstract: Liver transplantation is an exemplar model of complex surgery and the only curative option
for patients with end-stage liver disease. Although historically associated with poor outcomes, liver cancer
management has also been revolutionised with liver transplantation and in some instances, survival outcomes
are comparable to surgical resection. As such, the key elements underpinning the major advances in surgical
technique, immunological therapies and allocation policies combined with improved patient and graft
survival outcomes have created a huge demand for organ donation. Despite improvements in donor and
recipient selection, there is a persistent disparity between organ supply and demand. Candidate wait-list
mortality and dropout rates remain problematic and this concern has resulted in increased efforts to expand
the donor pool to meet the unmet needs of the population. This is even more challenging when coupled with
an ever-growing recipient pool, candidate waiting lists and an ageing population. Over the past two decades,
there has been a considerable focus on extended criteria organs, donations after cardiac death and alternative
avenues for marginal liver use. With careful donor selection and recipient matching, these livers may help
bridge the gap between supply and demand and placate the ever-expanding recipient pool. Here, we present
a summary of recent developments by the transplant community addressing the issues of a growing donor
and recipient pool.
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Introduction
The number of candidates added to the transplant wait
list continues to grow. In 2019, 8,896 liver transplants
were performed in the United States (US) and the rate
has been gradually increasing over the last decade (1).
The current annual transplant rate of adult candidates
actively listed on the wait list is 58.7% in the US and
has increased incrementally compared to previous years.
Current 1-, 3- and 5-year survival rates are 91.8%, 83.8%
and 76.1%, respectively, and liver transplantation (LT) is
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being considered for a growing list of conditions evident by
the expanding recipient pool and waiting lists. Despite the
benefits of LT, the scarcity of organs is a universal concern
and there have been several attempts by the transplant
community to propose strategies to overcome the deficit.
This has led to the consideration of livers which were
previously considered unsuitable for transplantation and
efforts to optimize “marginal” organs using innovative
machine technology. We, herein, provide a brief overview
of the existing approaches by the transplant community to
expand the donor and recipient pool for LT.
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Extended criteria donation to increase the donor
pool
The disparity between supply and demand has led to
the consideration of extended criteria donor (ECD)
liver allografts or “marginal donors” which do not meet
the traditional criteria for organ donation. The aging
population, longer life expectancy rates and the rising
incidence of several metabolic conditions such as obesity,
diabetes and fatty liver disease are all important factors
contributing to poor donor quality. Such issues are projected
to decrease donor liver utilisation rates from 78% to 44% if
ECDs are not included in the pool (2). While these organs
were previously avoided due to the fear of primary nonfunction (PNF) or delayed graft function (DGF), they are
now increasing used with the goal of improving access
to transplantable organs (3). The underlying concern is
the graft’s susceptibility to ischemia/reperfusion during
the transplantation process, adding to graft dysfunction
and poor regeneration (4). Despite this risk, ECDs have
played an important role in expanding the donor liver pool
with compelling evidence demonstrating their ability to
reduce wait list mortality and exhibit recipient outcomes
comparable to standard liver donations (5,6). There is
no universally accepted definition for what constitutes an
ECD, however, frequently cited characteristics are advanced
donor age, donation after cardiac death (DCD), hepatic
steatosis, split liver transplantation (SLT), and donors with
an infectious risk or previous malignancy (3,7,8).
Accepting donors with an advanced age
The use of livers from older donors is becoming more
frequent in modern practice, despite the concern of DGF
during the immediate post-operative period (7,9,10). No
clear age cut-off exists and several transplant units are
expanding that which is considered an acceptable donor age
in an effort to match the increased demand to the ageing
population demographic and available donor pool (11).
In 2014, 8% of liver donors from the US were 65 years and
older and this group increased further to 10% in recent
Organ Procurement and Transplantation Network (OPTN)
data (12,13). In a report from the European Liver Transplant
Registry, Adam et al. observed that 29% of donors were
older than 60 years and 11% were 65 years or older (14).
Some studies have reported acceptable outcomes in livers
from older donors. In an early study by Zapletal et al.
comparing liver allografts from donors both older and
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younger than 80 years, comparable results were achieved
in the postoperative course and older livers grafts were
functionally stable at discharge (15). Several other units
mirrored similar results in liver allografts from donors over
60 years and in some studies favourable outcomes were
achieved from donors older than 70 years as the transplant
community continues to explore an acceptable upper age
limit (16-18). In a recent study using the United Network
for Organ Sharing (UNOS) database, Haugen et al.
reported a significantly lower 5-year cumulative mortality
rate for patients who accepted livers from donors >70 years
when compared to a matched control group who declined
the same offer (23% vs. 41%) and the authors demonstrated
a substantial long-term survival benefit in the former
group (19). Despite these favourable outcomes, judicious
matching of older donors is paramount as these grafts are
more susceptible to ischemia reperfusion injuries, biliary
complications, a slight preponderance for hepatic artery
thrombosis and the risks are particularly heightened in
donors with hepatitis C (17,20,21).
Increasing DCD
Livers from donors with irreversible brain injury, not
meeting the criteria for brain death, have resulted in the
expansion of the donor pool. A study by Saidi et al. reported
an increase in the utility of DCD organs from 4.9% to
11.7% during a 10-year study period (22). In the case of
LT, recent OPTN data suggests an increase from 4.8% to
6.9% in DCD livers between 2008 and 2018 (12). Several
studies comparing DCD livers with standard brain-dead
donors (DBD) have demonstrated poorer allograft and
patient survival rates in the latter. This is likely related to
the longer ischemia time associated with DCD donors,
commencing from the time of extubation until cold
perfusion, which can be highly variable. A large multicentre
study of 2,572 liver transplants comparing DCD and DBD
livers identified that 3-year graft loss and recipient mortality
were twice as high with DCDs (23). In contrast, a study by
Taner et al. noted no differences in 1-, 3- and 5-year patient
survival rates between DBD and DCD groups and similar
comparable outcomes for graft survival (24). In an effort to
determine factors leading to graft loss, the authors identified
a link between the asystole to cross clap duration and the
development of ischemic cholangiopathy, an important and
feared consequence of DCDs. Nonetheless, DCDs can
significantly and safely expand the donor pool when used
with caution, adhering to a warm ischemia time less than
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30 minutes, using donors younger than 50 years and limiting
cold ischemia time (7,8). Future efforts to minimize ischemia
times and expand the upper age cut-off will further increase
the utility of DCD livers and expand the donor pool.
The use of steatotic livers
The rising incidence of obesity and metabolic syndromes
has led to the commensurate rise in non-alcoholic fatty liver
disease (NAFLD), with a population prevalence of up to
30% in Western societies (25,26). These rising incidences
and prevalence rates have seen parallel increases in potential
donors with hepatic steatosis. Traditionally, steatotic
allografts were avoided in LT for posing significant clinical
challenges in terms of early graft dysfunction and PNF. An
early study by Spitzer and colleagues analyzing a large US
registry of transplant recipients conclusively established
that livers with 30% or greater macrovesicular steatosis
were associated with lower 1-year survival rates (27).
Similar studies have demonstrated unfavourable outcomes
in the use of grafts with moderate (30–60%) and severe
(>60%) steatosis, largely due to the increased susceptibility
of steatotic grafts to ischemia reperfusion injuries (28,29).
However, in an effort to further expand the donor pool,
fatty livers are increasingly considered for transplantation
and form a major component for ECDs. In well matched
cases, mild steatosis may have a minimal impact on
reperfusion injury and post-transplant hepatic functionality.
A study by Dutkowski and colleagues analysed both US
and European liver transplant registries and determined
grafts with microvesicular and 30% or less macrovesicular
steatosis can be used safely with outcomes comparable to
non-steatotic livers (30). Acceptable outcomes were also
achieved in steatosis greater than 30% with careful risk
adjustment, although this remains controversial. Similar
studies assessing the suitability of steatotic grafts have
also considered the use of moderate to severely steatotic
allografts with somewhat acceptable post-transplant
outcomes, provided they are supplied by low-risk donors
(31,32). Continuing to extend the upper limits of steatosis
and define the acceptability of steatotic grafts will still be a
matter for debate, however, the integration of these grafts
into the donor pool has been a key element in providing
more livers for transplant.
Considering donors with an increased infectious risk
The use of donors with exposure to hepatitis B (HBV) or
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C (HCV) virus has been more acceptable in current times,
albeit previously met with strong objection due to initial
concerns regarding the introduction of aggressive viral
strains to immunosuppressed recipients. In the context of
HCV, there has been a shift in previous attitudes and recent
OPTN data reports an increase in the number of livers
recovered from hepatitis C positive donors and the number
of wait-list candidates willing to accept these livers (12).
Rigorous matching remains pertinent and younger donors
are preferred due to the fear of increased fibrosis in
recipients when older HCV positive donors are used (33).
Hepatitis C positive recipients transplanted with positive
donors have demonstrated comparable outcomes to those
receiving HCV negative livers (34,35). In an effort to
further expand the donor pool for all patients, transplanting
HCV positive livers into HCV negative patients, with
the addition of effective antiviral regimens, has seen some
promise in terms of long-term outcomes. Chhatwal and
colleagues report compelling evidence demonstrating that
accepting HCV positive livers for all donors may increase
life expectancy and decrease wait-list mortality (36).
Additionally, a recent study by Cotter and colleagues
analysing data from 2008 to 2018 reports increased 3-year
graft survival rates from 79% to 88% in HCV negative
donors receiving HCV positive livers and direct-acting
antiviral therapies (37). Similarly, the increased use of
organs from HBV positive donors has the potential to
expand the donor pool. In a study by Cholongitas and
colleagues, recipients without prior exposure to HBV
receiving antiviral prophylaxis showed excellent outcomes
following transplantation with HBV positive livers (38).
Effective HBV prophylaxis in the form of hepatitis B
immunoglobulin or oral antiviral therapy have led to a
reduction in HBV transmission and viral recurrence in
select donors and some units have included these in their
donor pool (39-41). While this practice is still limited to a
few centres because of the concern of viral reactivation in
recipients, more effective prophylaxis could encourage the
inclusion of such grafts for the wider recipient pool.
Split liver grafts
Splitting livers (SLT) into two potential grafts has been
explored as another method to increase donor supply,
however, their use has been relatively stable over the last
decade (12). This procedure usually involves donating
the left lateral segment to a pediatric recipient and
transplanting the right trisegment into an adult, although
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splitting the liver into a right and left lobe for two adults
has also been described (7,42). It has been estimated that
up to 20% of livers are suitable for splitting, however,
the technique is limited to specialist centres due to the
complexity of the procedure and the heightened risk
of biliary and vascular complications (42,43). A study
by Vagefi and colleagues assessing outcomes in SLT
recipients reported 93%, 77%, and 73% and 89%, 76%,
and 65% overall patient and graft survival rates at 1-, 5and 10-years (44). A similar study by Doyle and colleagues
demonstrated 95.5%, 89.5% and 89.5% 1-, 5- and 10-year
survival rates in adults recipients of SLT, comparable
to whole organ (WLT) recipients (45). In contrast, a
multicentre study by Aseni demonstrated lower 5-year
survivals in patients receiving SLT compared to WLT
(63.3% vs. 83.1%) (46). While SLT continues to be limited
to centres with technical expertise, they require high quality
grafts to gain acceptable post-operative outcomes and
currently only represent 1% of US liver transplants and 6%
of transplants in Europe (12,47).
Living donor LT (LDLT)
First reported in the US in 1998, LDLT is an additional
mechanism to expand the donor pool and increase
organ availability. Both right and left lobes can be used
in transplantation with the latter generally reserved for
small sized recipients and paediatric patients. A left lobe
resection has the added benefit of removing a smaller
portion of liver from the living donor. By contrast, the
right lobe, mainly reserved for adult patients, accounts for
up to two-thirds of the total liver mass and can potentially
cause significant harm to the donor if the remnant liver
volume is too small or unhealthy to support the metabolic
and physiological needs of the recipient. The number of
LDLTs has increased slowly over the past 2 decades and
recent US liver registry data reports LDLTs accounted for
up to 4.4% of liver donations in 2018 (12,48). Although
modest, the increase in LDLTs has been largely driven
by a rise in the number of unrelated directed donors (12).
The number of left lobe resections has also decreased
corresponding with a parallel rise in right lobe donations.
A study by Shah and colleagues demonstrated significantly
shorter mean waiting times between right lobe donations
and patients awaiting grafts from deceased donors (49).
Although LDLT has the advantage of optimizing the timing
of surgery, comprehensive donor work-up and minimizing
cold ischemia and organ transport times, the process still
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poses a risk to the donor and can subject a healthy person
to a substantial burden (50). Overall donor mortality rates
range from 0.2% to 0.8% with some studies reporting a
slight donor survival benefit in right lobe donations (51-53).
Graft failure is reported to occur in up to 7.8%, 14.6% and
26.5% of LDLTs at 1, 3 and 5 years with more favourable
outcomes demonstrated in non-hepatocellular carcinoma
(HCC) diagnoses and Model for End-stage Liver Disease
(MELD) scores less than 20 (12). Furthermore, a study by
She and colleagues reported, in an analysis of 218 patients,
significantly better 5-year graft survival rates in using
right lobe LDLT, albeit comparable 5-year patient survival
rates (54). These findings were contrasted by Olthoff and
colleagues who in a large multicentre study of 963 LDLTs
demonstrated similar graft survival rates in right and left
lobe LDLTs with decreasing rates of graft failure associated
with greater centre experience (55). However, despite these
promising results several studies have reported inconsistent
graft survival rates between LDLT and standard cadaveric
liver donations. Some analyses have demonstrated decreased
graft survival rates in LDLT (56,57), while more recent
studies appear to demonstrate similar long-term 10-year
survival rates between patients receiving grafts from
living donors and deceased donor grafts (55). For this
reason, LDLT is reserved for high volume centres with
specialist expertise due to the complexities of the procedure
which requires a deep understanding of the physiological
requirements of the graft to ensure sufficient hepatic
regeneration and minimize donor risk.
Machine perfusion to optimise liver quality
The recent arrival of ex-vivo machine perfusion techniques
is beginning to change the landscape of how “marginal”
livers are utilized and has the potential to fully expand the
donor pool and reduce liver discard. Hypothermic and
normothermic machine perfusion technologies have shown
promising results in minimising injury to DCD grafts and
steatotic livers (58,59). Schlegel and colleagues provided
5-year outcome data on patients receiving DCD liver
transplants following treatment with hypothermic oxygen
perfusion prior to transplantation. Outcomes of treated
DCD livers were similar to DBD and superior to untreated
DCDs with significantly less graft loss events (58). A recent
study reported similar encouraging results in transplanting
previously rejected liver allografts following the application
of normothermic machine perfusion (60). While the
optimal temperature setting continues to be debated, this
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innovation may salvage various extended criteria allografts
and modify their risk for routine use, ultimately expanding
the donor pool.
Expanding the recipient pool
Despite several strategies attempting to increase the liver
donor pool, the recipient pool continues to expand and
wait list mortality remains a concern. The wider acceptance
of LT and improved outcomes has allowed clinicians to
consider transplanting patients they were historically
reluctant to do so. According to OPTN data, alcoholic
liver disease, non-alcoholic steatohepatitis (NAFLD) and
HCC are the most common conditions leading to LT in the
US and the increased public burden of these diseases has
contributed to an increased number of patients requiring
transplantation (12). The healthcare prevalence of alcoholic
liver disease continues to grow. A study by Jinjuvadia and
colleagues observed a substantial increase in the number of
alcohol-related hospitalizations over an 8-year period (61).
In 2018, the proportion of candidates listed for ALD
increased considerably from 22.7% to 29.8% over a 10-year
period (12). Similarly, NAFLD is becoming more prevalent
and has been linked with the alarming growth rate of
population obesity (26). Several models have projected
this to become the leading cause for LT as more patients
progress to decompensated cirrhosis warranting curative
intervention. In addition, global trends have demonstrated
a rising incidence in the diagnosis of HCC, although the
causes of this are still unclear (62). The evidence regarding
transplanting HCC patients, particularly since the
introduction of the Milan criteria, has been promising for
unresectable disease and more patients are being considered
for LT and form a substantial portion of the recipient pool
(63,64). The proportion of HCC candidates awaiting LT
increased from 3.4% to 9.8% between 2008 and 2018 (12).
There has been some interest in expanding the current
eligibility guidelines for HCC. Yao and colleagues report
similar LT outcomes in HCC patients with tumours as
large as 6.5 cm or less than 4 nodules smaller than 4.5 cm
and a total tumour diameter less than 8 cm, arguing that the
current Milan staging is too restrictive (65). Additionally,
the success of chemotherapy has seen several patients with
advanced disease downstaged to liver disease within the
Milan criteria and meeting eligibility for LT (66). Several
other hepatic tumours have been added to the recipient pool
with promising results in some units. In a small prospective
case-series by Lunsford and colleagues, patients with locally

© Chinese Clinical Oncology. All rights reserved.

Page 5 of 8

advanced intrahepatic cholangiocarcinoma and stable
disease from neoadjuvant therapy had 1-, 3- and 5-year
survival rates of 100%, 83.3%, and 83.3% respectively.
While the study only involved a small selected group of
patients, LT showed promise (67). In addition, despite
initial reluctance, some units have started to reconsider
LT for colorectal liver metastases (CLM). In a study
comparing LT and chemotherapy for nonresectable CLM,
LT observed better 5-year survival rates (56% vs. 9%) (68).
Although, this has yet to gain widespread acceptance,
better expertise in LT and cancer biology could see a rapid
expansion in the recipient pool and the inclusion of patients
who were previously contraindicated for LT.
Future directions
The transplant community continues to evolve and active
efforts to expand both the donor and recipient pools are
in constant motion. LT remains a curative option for a
wide spectrum of the population and expertise in surgical
technique, immunotherapy and post-operative care are
among the several elements underpinning the continually
improved outcomes reported internationally. While
breakthroughs in machine perfusion and chemotherapy
are still underway, the role of social media in increasing
awareness of organ donation may be a feasible route. Kumar
and colleagues, in collaboration with Facebook, created
a mobile application whereby waitlisted candidates were
allowed the opportunity to create a post and communicate
their experience with organ failure and the need for live
organ donation (69). Impressively, candidates who engaged
with the app were 6.6 times more likely to have a donor
come forward compared with matched controls and the
app was received well overall (69). As the boundaries of
social media platforms continue to push limits, some have
advocated for the increased use of social media billboard
approaches and targeted campaigns to shift societal
perspectives of organ donation and gain public attention (70).
Conclusions
In summary, LT is a growing field with boundless potential.
The disparity between patients who need a liver transplant
and those who receive one is a constant concern, and while
significant progress has been made in the field, further
efforts from the national and international consortia are
warranted. Pre-existing criteria for LT and recipient
boundaries are continually challenged and expanded and,
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when coupled with judicious matching and careful patient
selection, excellent patient and graft survival results are an
endless opportunity.
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